You are here

Research into the treatment and prevention of cystic fibrosis lung disease in young children wins prestigious award

Research News
Monday, December 12, 2016 - 10:45am
Associate Professor Sarath Ranganathan receives  inaugural Cystic Fibrosis Australia Governor-General's Patron's Awards at Admiralty House in Sydney
On Monday 21 November 2016 the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) were announced as the winners of the inaugural Cystic Fibrosis Australia Governor-General's Patron's Awards at Admiralty House in Sydney.

His Excellency General the Honourable Sir Peter Cosgrove AK MC (Retd) and Patron of Cystic Fibrosis Australia (CFA) generously hosted the awards in celebration and recognition of the great work and fortitude displayed by the cystic fibrosis (CF) community.

Received by Associate Professor Sarath Ranganathan, Group Leader and Principal Research Fellow at Murdoch Children's Research Institute on behalf of the AREST CF team, the prestigious Patron's Awards honour a Community Fundraiser who has shown both a personal and financial commitment to the CF cause where their work has resulted in valuable advocacy and awareness building.

The AREST CF project focuses on the assessment, treatment and prevention of CF lung disease in children under the age of seven. It targets disease prevention commencing at diagnosis in children with CF identified by newborn screening.

The project aims to significantly extend the age at which CF patients begin to experience failing lung health, which includes reducing the onset and prevalence of bronchiectasis, the main disease mechanism causing severe lung damage.

Given the AREST CF project is completely embedded in centre care programs the research has a greater chance of improving patient care and ensuring it is responsive to patient needs, rather than simply being 'trapped in the laboratory'. 

This research project is a collaboration of specialist paediatric CF centres in Western Australia and Victoria with a team of over 25 internationally recognised scientists, researchers, doctors and clinicians dedicated to improving respiratory health and outcomes in children with CF.

The team has been working on solutions since 2005 and has already impacted early CF lung disease detection through collaboration with researchers in the United States, Canada and France. These overseas colleagues have direct links to the pharmaceutical industry, greatly enhancing opportunities for drug development and large-scale clinical trials.

To learn more about ARRST CF visit: